BMS, Biocon Team Up To Rekindle Oral Insulin Hopes
This article was originally published in PharmAsia News
Executive Summary
After faltering last year with clinical development of its oral insulin, Biocon’s long hunt for a partner ends with Bristol-Myers Squibb, which signed a carefully worded “exclusive option agreement.”
You may also be interested in...
Bristol Signals Dapaglifozin’s Back On Track, Plans FDA Resubmission
Bristol suggests FDA has had a change of heart on the evolving filing package for diabetes drug dapagliflozin. Meanwhile, the company sees no additional U.S. regulatory hurdles ahead for the eagerly awaited, novel oral anticoagulant Eliquis.
India's Biocon Says Primary Endpoints Set For Oral Insulin May Have Been "Harsh"; Reinforces Goal To Develop Drug With Global Partner
MUMBAI - Indian biotechnology firm Biocon has reinforced its ambitions to bring to market an orally delivered insulin and said it stays firmly on track as it found several "unique and positive" takeaways from its recently concluded Phase III clinical trials in India
Biocon's Oral Insulin Fails To Meet Primary Endpoint; Unfazed, Company Says Stage Set For Partnering Talks With Global Pharma
MUMBAI - India's flagship biotechnology company Biocon suffered a significant setback to its most ambitious research project - an orally delivered insulin - that failed to meet its primary end point of lowering HbA1c levels by 0.7 percent in a clinical study concluded recently in India